Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NTRP Neurotrope (NTRP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesShort InterestTrends About Neurotrope Stock (NASDAQ:NTRP) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Neurotrope alerts:Sign Up Key Stats Today's Range$1.46▼$1.9250-Day Range$0.92▼$1.0552-Week Range$0.68▼$3.85Volume31,095 shsAverage Volume32,512 shsMarket Capitalization$2.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.Read More… Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Receive NTRP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurotrope and its competitors with MarketBeat's FREE daily newsletter. Email Address NTRP Stock News HeadlinesNextTrip (NASDAQ:NTRP) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comNextTrip, Inc.: NextTrip Introduces Group Booking Technology Platform to Streamline and Simplify Travel for GroupsAugust 2, 2024 | finanznachrichten.deJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.November 24, 2024 | Priority Gold (Ad)NextTrip, Inc. (NTRP) Stock Price, News, Quote & History - Yahoo FinanceMay 18, 2024 | finance.yahoo.comNextTrip, Inc. (NTRP) Latest Stock News & Headlines - Yahoo FinanceApril 30, 2024 | finance.yahoo.comNextTrip Inc NTRPApril 4, 2024 | morningstar.comAlzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsightAugust 17, 2023 | finance.yahoo.comAt 6.9% CAGR, Global Erectile Dysfunction Drugs Market Size & Share Will Hit US$ 5.94 Billion | Industry Trends, Demand, Growth, Value, Analysis & Forecast Report by Zion Market Research - Yahoo FinanceJune 22, 2022 | finance.yahoo.comSee More Headlines NTRP Stock Analysis - Frequently Asked Questions How were Neurotrope's earnings last quarter? Neurotrope, Inc. (NASDAQ:NTRP) issued its quarterly earnings results on Tuesday, October, 30th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.05. What other stocks do shareholders of Neurotrope own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurotrope investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Bristol-Myers Squibb (BMY), Intel (INTC), Meta Platforms (META) and Pfizer (PFE). Company Calendar Last Earnings10/30/2018Today11/24/2024Next Earnings (Estimated)1/21/2025Fiscal Year End2/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Discretionary Industry Transportation services Sub-IndustryN/A Current SymbolNASDAQ:NTRP CUSIPN/A CIK1513856 Webwww.neurotropebioscience.com Phone973-242-0005Fax505-424-3174Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax Margin-904.14% Return on Equity-286.56% Return on Assets-100.34% Debt Debt-to-Equity RatioN/A Current Ratio0.27 Quick Ratio0.27 Sales & Book Value Annual Sales$630,000.00 Price / Sales3.97 Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book0.53Miscellaneous Outstanding Shares1,420,000Free Float1,283,000Market Cap$2.50 million OptionableNo Data Beta1.67 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:NTRP) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored#1 Crypto of 2024Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurotrope, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurotrope With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.